144 related articles for article (PubMed ID: 38584159)
1. Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
Huffman MD; Baldridge AS; Lazar D; Abbas H; Mejia J; Flowers FM; Quintana A; Jackson A; Kandula NR; Lloyd-Jones DM; Persell SD; Khan SS; Paparello JJ; Chopra A; Tripathi P; Vu MH; Chow CK; Ciolino JD
Hypertens Res; 2024 Jun; 47(6):1668-1677. PubMed ID: 38584159
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Chow CK; Atkins ER; Hillis GS; Nelson MR; Reid CM; Schlaich MP; Hay P; Rogers K; Billot L; Burke M; Chalmers J; Neal B; Patel A; Usherwood T; Webster R; Rodgers A;
Lancet; 2021 Sep; 398(10305):1043-1052. PubMed ID: 34469767
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
4. Ambulatory blood pressure after 12 weeks of quadruple combination of quarter doses of blood pressure medication vs. standard medication.
Nolde JM; Atkins E; Marschner S; Hillis GS; Chalmers J; Billiot L; Nelson MR; Reid CM; Hay P; Burke M; Jansen S; Usherwood T; Rodgers A; Chow CK; Schlaich MP
J Hypertens; 2024 Jun; 42(6):1009-1018. PubMed ID: 38501351
[TBL] [Abstract][Full Text] [Related]
5. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
[TBL] [Abstract][Full Text] [Related]
6. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure-lowering efficacy and safety of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled essential hypertension: a multicenter, randomized, double-blind, controlled trial.
Mourad JJ; Amodeo C; de Champvallins M; Brzozowska-Villatte R; Asmar R;
J Hypertens; 2017 Jul; 35(7):1481-1495. PubMed ID: 28306636
[TBL] [Abstract][Full Text] [Related]
8. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Chow CK; Thakkar J; Bennett A; Hillis G; Burke M; Usherwood T; Vo K; Rogers K; Atkins E; Webster R; Chou M; Dehbi HM; Salam A; Patel A; Neal B; Peiris D; Krum H; Chalmers J; Nelson M; Reid CM; Woodward M; Hilmer S; Thom S; Rodgers A
Lancet; 2017 Mar; 389(10073):1035-1042. PubMed ID: 28190578
[TBL] [Abstract][Full Text] [Related]
9. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
[TBL] [Abstract][Full Text] [Related]
10. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study.
Zhang Y; Agnoletti D; Safar ME; Blacher J
Hypertension; 2011 Aug; 58(2):155-60. PubMed ID: 21747047
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
12. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study.
Neldam S; Edwards C; Jones R;
Curr Med Res Opin; 2011 Nov; 27(11):2145-53. PubMed ID: 21955225
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Schweizer J; Ulmer HJ; Benduhn H; Klebs S
Curr Med Res Opin; 2011 Jan; 27(1):131-40. PubMed ID: 21117946
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Edes I;
Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Volpe M; Christian Rump L; Ammentorp B; Laeis P
Clin Drug Investig; 2012 Oct; 32(10):649-64. PubMed ID: 22909147
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
Sohn IS; Kim CJ; Ahn T; Youn HJ; Jeon HK; Ihm SH; Cho EJ; Chung WB; Chae SC; Kim WS; Nam CW; Park SM; Choi JY; Kim YK; Hong TJ; Lee HY; Cho JH; Shin ES; Yoon JH; Yang TH; Jeong MH; Lee JH; Park JI
Clin Ther; 2017 Aug; 39(8):1628-1638. PubMed ID: 28734660
[TBL] [Abstract][Full Text] [Related]
18. Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.
Chow CK; Atkins ER; Billot L; Chalmers J; Hillis GS; Hay P; Neal B; Nelson M; Patel A; Reid CM; Schlaich M; Usherwood T; Webster R; Rodgers A
Am Heart J; 2021 Jan; 231():56-67. PubMed ID: 33017580
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Wang JG; Yukisada K; Sibulo A; Hafeez K; Jia Y; Zhang J
J Hypertens; 2017 Apr; 35(4):877-885. PubMed ID: 28030431
[TBL] [Abstract][Full Text] [Related]
20. Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Zemmrich C; Lüders S; Gansz A; Sturm CD; Fimmers R; Nadal J; Schmieder RE; Schrader J; Bramlage P
J Clin Hypertens (Greenwich); 2013 Nov; 15(11):815-9. PubMed ID: 24102831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
